Selective Whole Blood Lipoprotein Apheresis to Prevent Pancreatitis in Drug Refractory Hypertriglyceridemia

Anders Hovland¹,³, Randolf Hardersen¹, Tom Eirik Mollnes²,⁴, Knut Tore Lappegård¹,³

¹Department of Internal Medicine and ²Somatic Research Laboratory, Nordland Hospital. Bodø, Norway. Institutes of ³Clinical Medicine and ⁴Medical Biology, University of Tromsø. Tromsø, Norway

ABSTRACT

Context Severe hypertriglyceridemia is a known cause of acute pancreatitis, and apheresis treatment, most commonly plasmapheresis, has been used to treat patients with drug refractory hypertriglyceridemia for more than 30 years. Case report We report a case in which a woman with Crohn’s disease and type 2 diabetes mellitus developed recurrent episodes of acute pancreatitis due to extreme hypertriglyceridemia. After the initiation of lipoprotein apheresis from whole blood, a marked reduction of triglyceride and lipoprotein levels was observed. Some inflammatory parameters were increased even if most of the cytokines were not detectable, indicating good biocompatibility of the filter. Conclusions Triglyceride levels were lowered after initiating selective lipoprotein apheresis. More importantly, the patient did not experience any relapses of pancreatitis after the treatment was started. Hence this treatment is feasible in drug refractory hypertriglyceridemia, but the treatment concept needs to be tested in additional studies.

INTRODUCTION

Severe hypertriglyceridemia is known to cause acute pancreatitis, perhaps however at higher levels of triglycerides than previously thought [1]. Several mechanisms for the disease have been proposed, including the hydrolysis of triglycerides forming free fatty acids inducing inflammation, chylomicrons inducing hyperviscosity leading to ischemia, and finally genetic predisposition [2, 3]. Furthermore, cytokines seem to play a pivotal role in acute pancreatitis including the systemic responses [4]. Apheresis for lowering triglyceride levels was first reported in 1978 [5], and plasmapheresis has since then been used for refractory hypertriglyceridemia [6, 7]. We report a case in which a patient with drug refractory hypertriglyceridemia and recurrent episodes of pancreatitis was treated with direct adsorption of lipoprotein during hemoperfusion, and we present its effect on the lipid profile, cytokines and clinical course.

CASE REPORT

A 24-year-old woman was diagnosed with Crohn’s disease in 1983 and treated with salazopyrine for two years. The inflammatory bowel disease was stable for the next twenty years. Abdominal ultrasound scans demonstrated hepatic steatosis. In 2008, an ileocecal resection was performed due to stenosis in the terminal ileum. Her inflammatory bowel disease has been stable without medication since then.

In 1997, she was diagnosed with hypertriglyceridemia with a serum triglyceride level of 17 mmol/L (reference range: 0.5-2.6 mmol/L; or 1,513 mg/dL, reference range: 44-230 mg/dL), and was started on omega-3 fatty acids (5 g/day). At the same time, type 2 diabetes was detected, and metformin and subcutaneous insulin were started. No other causes of the hypertriglyceridemia were found, and there were no signs of hereditary hypertriglyceridemia. Due to poor control of her hypertriglyceridemia, she was started on bezafibrate and she was eventually switched to fenofibrate (200 mg once daily) due to muscle pain from the bezafibrate and, in 2008, she was also started on nicotinic acid. From 1997 to 2008, her triglyceride levels were in the range of 5-50 mmol/L (445-4,450 mg/dL). Her hemoglobin A1c was 7.0% (reference range: 4.5-6.0%). She was not overweight and her diet was balanced. In 2007, she developed angina pectoris,
and she was treated with percutaneous coronary intervention with a stent in her right coronary artery. Her average triglyceride levels increased from 2008 (Figure 1) and, in June 2009, she was admitted to our hospital due to abdominal pain. A CT scan of the abdomen was consistent with acute pancreatitis even though her serum lipase was within normal range. She was treated conventionally including rehydration, and the symptoms were resolved. She was re-hospitalized in September 2009 and January 2010 due to acute pancreatitis diagnosed by CT scans. These episodes were resolved uneventfully as well.

Due to the unsatisfactory control of her triglyceride levels as well as recurrent episodes of pancreatitis, it was decided to start apheresis treatment. In January 2010 a venous catheter was surgically inserted in her right internal jugular vein. Her first whole blood apheresis was performed at the end of January 2010. We used a Liposorber® D DL-75 column (Kaneka Co., Osaka, Japan) with a Kaneka MA-03 (Kaneka Co., Osaka, Japan) machine. DL-75 is a whole blood adsorption filter and part of the Liposorber® D system. This filter utilizes dextran sulphate cellulose beads for adsorption of lipoprotein. It can be modified according to particle size and allows perfusion and adsorption of lipoproteins directly from whole blood. Anticoagulation is mandatory during apheresis treatment, and acid citrate dextrose-A was used. Due to the known calcium lowering effect of this anticoagulant, intravenous calcium chloride was administered during the treatment. The first treatment was carried out for 60 minutes (whole blood volume 3,500 mL), only to determine how the treatment was tolerated; subsequently, lipoprotein apheresis duration was approximately two hours (whole blood volumes more than 6,000 mL). Treatment was performed weekly. The first three complete aphereses were monitored closely, including lipoprotein and cytokine measurements.

Triglyceride levels and total cholesterol were reduced by about one third. Cytokines were measured using a multiplex assay containing 27 different inflammatory mediators: IL (interleukin) 1 beta (IL-1beta), IL-1 receptor antagonist (IL-1ra), IL-2, IL-4, IL-5, IL-6, IL-7, IL-8 (CXCL8), IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, etokain (CCL11), basic fibroblast growth factor (FGF), G-CSF, GM-CSF, IFN-gamma, chemokine (C-X-C motif) ligand 10 (IP-10 or CXCL10), monocyte chemoattractant protein 1 (MCP-1 or CCL2), macrophage inflammatory protein 1-alpha (MIP-1 alpha; or CCL3), MIP-1 beta (or CCL4), platelet derived growth factor (PDGF), regulated upon activation T cell expressed and secreted (RANTES or CCL5), TNF-alpha and vascular endothelial growth factor (VEGF). Most of the cytokines, including TNF-alpha and IL-6, were below the detection limits whereas IP-10 and MIP-1 beta showed a consistent increase during the apheresis procedure (Table 1). The patient did not experience any side effects from the treatment and, up to the writing of this paper (June 2010), she has not had any relapses of pancreatitis.

**DISCUSSION**

We report a case in which a patient with hitherto uncontrolled hypertriglyceridemia and several episodes of acute pancreatitis had her triglyceride levels reduced to less than 20 mmol/L (1,780 mg/dL) with whole blood lipoprotein apheresis without recurrent episodes of pancreatitis. To our knowledge, this is the first case which describes repeated selective lipoprotein apheresis from whole blood in hypertriglyceridemia. In Crohn’s disease, there is an increased risk of pancreatitis, even in the absence of gallstones or medications prone to causing pancreatitis, and the pathogenesis is thought to be immunological [8]. However, although our patient had previously been diagnosed with Crohn’s disease, she had not received any treatment for this until this study, and reported no symptoms relevant to Crohn’s disease. Therefore, it is unlikely that the recurrent episodes of pancreatitis were linked to her inflammatory bowel disease.

---

**Table 1.** Changes in laboratory parameters before and after the three first apheresis treatments.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Apheresis 1</th>
<th>Change</th>
<th>Apheresis 2</th>
<th>Change</th>
<th>Apheresis 3</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total cholesterol (mmol/L)</td>
<td>8.2</td>
<td>-20%</td>
<td>8.1</td>
<td>-37%</td>
<td>5.8</td>
<td>-36%</td>
</tr>
<tr>
<td>(mg/dL)</td>
<td>320</td>
<td></td>
<td>316</td>
<td></td>
<td>226</td>
<td></td>
</tr>
<tr>
<td>Triglycerides (mmol/L)</td>
<td>21</td>
<td>-19%</td>
<td>17</td>
<td>-35%</td>
<td>12</td>
<td>-30%</td>
</tr>
<tr>
<td>(mg/dL)</td>
<td>1,869</td>
<td></td>
<td>1,513</td>
<td></td>
<td>869</td>
<td></td>
</tr>
<tr>
<td>Chemokine ligand 10 (IP-10; ng/L)</td>
<td>874</td>
<td>+288%</td>
<td>923</td>
<td>+230%</td>
<td>814</td>
<td>+292%</td>
</tr>
<tr>
<td>Macrophage inflammatory protein 1-beta (ng/L)</td>
<td>33.6</td>
<td>+114%</td>
<td>24.6</td>
<td>+180%</td>
<td>17.7</td>
<td>+382%</td>
</tr>
</tbody>
</table>

---

![Figure 1. Average levels of triglycerides. Values are averaged for 2006 through 2009; the values are then averaged for the first three months of 2010. The black arrow below the x-axis indicates the start of apheresis treatments in the latter part of January 2010.](image-url)
Most reports on apheresis associated with hypertriglyceridemia deal with plasmapheresis which typically lowers triglyceride levels by 60-70% in one session [6, 7, 9]. However, single and double filtration plasmapheresis do not selectively remove lipoproteins and triglycerides, and hence coagulation factors and immunoglobulins also are removed with possible adverse events including infections. Thus, we chose an approach with selective lipoprotein apheresis, although the treatment is not as effective for lowering triglycerides as the plasmapheresis techniques. However, until now triglyceride levels in our patient have been markedly reduced, and she has not experienced any more episodes of pancreatitis.

Cytokines play a role in the inflammatory response associated with acute pancreatitis [4] and our group has previously shown that different apheresis columns affect inflammatory biomarkers differently in patients with familial hypercholesterolemia [10]. In the current patient, we measured a wide range of inflammatory mediators. Most of the mediators were below the detection limit both before and after apheresis. However, IP-10 and MIP-1 beta increased 2-6-fold after apheresis. Whether this has any clinical relevance is uncertain, but it has recently been demonstrated that tumor necrosis factor promoter polymorphism plays a role in hypertriglyceridemia pancreatitis [11]. Thus, how the apheresis columns handle inflammatory biomarkers may be of interest. The fact that our patient had undetectable levels of TNF does not rule out a role for this mediator in acute pancreatitis as our samples were not collected during active inflammation. In conclusion, we have shown that selective whole blood lipoprotein apheresis is feasible for hypertriglyceridemia, resulting in a moderate reduction of triglyceride levels and apparent protection from pancreatitis without the undesired consequences of ordinary plasmapheresis.

Conflicts of interest There are neither conflicts of interest nor sources of financial support to declare

References